Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01264783 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of RNS60 Given by IV to Healthy Subjects
A Phase 1 study of Myocardial Infarct, sponsored by Revalesio Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01264783: Completed Phase 1 study of Myocardial Infarct, sponsored by Revalesio Corporation.
NCT01264783 is a Phase 1 study of Myocardial Infarct that has completed, run by Revalesio Corporation. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01264783, a Phase 1 study of Myocardial Infarct, has completed, sponsored by Revalesio Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
Primary Outcome
Safety and tolerability of RNS60 administered by IV infusion to healthy volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RNS60
Study Locations (1)
Kansas
- Quintiles, Inc. - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
What the finished NCT01264783 record still lists
NCT01264783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Myocardial Infarct appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01264783 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01264783 about?
NCT01264783 is a clinical study titled "Safety and Tolerability of RNS60 Given by IV to Healthy Subjects". The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
What is the current status of trial NCT01264783?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-07. Estimated completion is 2011-09.
What conditions does trial NCT01264783 study?
This clinical trial studies the following conditions: Myocardial Infarct.
What interventions are being tested in trial NCT01264783?
The interventions under investigation include: Placebo (DRUG), RNS60 (DRUG).
Who is sponsoring clinical trial NCT01264783?
This trial is sponsored by Revalesio Corporation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01264783 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarct
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01264783's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia